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ABSTRACT 
 
Purpose: To determine the time and risk factors for developing proliferative 
diabetic retinopathy (PDR) and vitreous hemorrhage (VH)  
Design: Multicenter, national cohort study  
Methods:  Anonymized data of 50,254 patient eyes with diabetes mellitus at 19 
UK hospital eye services were extracted at the initial and follow-up visits between 
2007 and 2014. Time to progression of PDR and VH were calculated with Cox 
regression after stratifying by baseline diabetic retinopathy (DR) severity and 
adjusting for age, gender, race, and starting visual acuity.  
Results: Progression to PDR in 5 years differed by baseline DR: No DR (2.2%), 
mild (13.0%), moderate (27.2%), severe non-proliferative diabetic retinopathy 
(NPDR) (45.5%). Similarly, 5-year progression to VH varied by baseline DR: No 
DR (1.1%), mild (2.9%), moderate (7.3%), severe NPDR (9.8%). Compared to no 
DR, the patient eyes that presented with mild, moderate, and severe NPDR were 
6.71, 14.80, and 28.19 times more likely to develop PDR, respectively. In 
comparison to no DR, the eyes with mild, moderate, and severe NPDR were 
2.56, 5.60, and 7.29 times more likely to develop VH, respectively.  
In severe NPDR, the eyes with intraretinal microvascular abnormalities (IRMA) 
had a significantly increased hazard ratio (HR) of developing PDR (HR 1.77, 95% 
CI 1.25-2.49, p=0.0013) compared to those with venous beading, while those 
with 4 quadrant dot blot hemorrhages (4Q DBHs) had 3.84 higher HR of 
developing VH (95% CI 1.39-10.62, p=0.0095).  
Conclusions: Baseline severities and features of initial DR are prognostic for 
PDR development. IRMA increases risk of PDR while 4Q DBHs increases risk of 
VH.  
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Short title 
Baseline severities and features of DR predict progression. 
 
Abbreviations 
4Q DBH: four quadrant dot blot hemorrhage 
DBH: dot blot hemorrhage 
DME: diabetic macular edema 
DR: diabetic retinopathy 
DRS: Diabetic Retinopathy Study 
EMR: electronic medical record 
ETDRS: Early Treatment Diabetic Retinopathy Study 
FA: fluorescein angiography 
IRMA: intraretinal microvascular abnormalities 
NA: not applicable 
NHS: National Health Service 
NPDR: non-proliferative diabetic retinopathy 
NVE: neovascularization elsewhere 
OCT: optical coherence tomography 
PDR: proliferative diabetic retinopathy 
RCT: randomized controlled trial 
UK: United Kingdom 
UK DR EMR: United Kingdom Diabetic Retinopathy Electronic Medical Record 
VA: visual acuity 
VEGF: vascular endothelial growth factor 
VH: vitreous hemorrhage 
WESDR: Wisconsin Epidemiologic Study of Diabetic Retinopathy 
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INTRODUCTION 
Diabetic retinopathy (DR) is the leading cause of blindness in working age adults 
worldwide.1 More than 5 million were affected in 2005 and this number is 
projected to triple to 16 million by 2050 in the US alone.2 Even though early 
detection of DR can substantially decrease the risk of blindness, the non-
adherence rate of diabetic retinopathy screening has been reported as high as 
69%.3 
The progression to vision-threatening proliferative diabetic retinopathy (PDR) 
primarily depends on the stage of DR severity. The Early Treatment Diabetic 
Retinopathy Study (ETDRS) has revealed that the risk of progression from 
severe non-proliferative diabetic retinopathy (NPDR) to proliferative diabetic 
retinopathy (PDR) is approximately 52% in one year.4 Since the time of ETDRS, 
the management of diabetes has changed significantly.5 Thus, more recent 
clinical trials or epidemiologic studies have revealed varying rates of PDR 
progression from baseline DR in 4 years ranging from 5.3 to 11.0%.6-10 
The key classification of DR was originally defined in the Airlie House 
Symposium in 1968 and modified in several landmark trials to date.11,12 In 
particular, the modified classification used in the ETDRS has been used widely in 
research settings but involved a complex scoring system ranging from 10 to 85 
and required comparison with the standard photographs.12 As a result, even 
more simplified, clinical classification systems are more commonly used 
nowadays.13,14 However, whether more granular, feature-based criteria can 
predict PDR progression in a large scale has not been studied to our knowledge. 
In addition, progression rates of retinopathy in the context of current systemic 
management have not been adequately explored with real world data.  This 
information will be important in guiding follow-up intervals on monitoring for 
diabetic retinopathy, advising the patient and their diabetic care team regarding 
progression risk, as well as the powering of clinical trials for interventions that 
may prevent the progression of diabetic retinopathy. 
The United Kingdom Diabetic Retinopathy Electronic Medical Record (UK DR 
EMR) Users Group database is unique in that each clinical feature of diabetic 
retinopathy is entered by physicians at baseline and at each retina clinic visit in a 
structured manner. The DR score is then generated automatically based on the 
ETDRS criteria by aggregating the recorded feature, thus providing us with an 
enriched clinical dataset to study the validity of clinical features in predicting DR 
progression. The purpose of our paper was to perform an EMR based 
epidemiologic study to determine current rates of DR progression in the UK study 
cohort and define the time to progression to PDR and vitreous hemorrhage (VH), 
two important clinical endpoints of DR, in diabetic patients who present to eye 
care providers for the first time. In addition, we sought to determine the clinical 
features of diabetic retinopathy that are most predictive of progression to PDR.  
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METHODS 
Ethics Approval 
This study was conducted in accordance with the Declaration of Helsinki and the 
UK Data Protection Act. The lead clinician and Caldicott Guardian, who are 
responsible for protecting confidentiality of patient information, at each 
participating center gave written approval for extraction of anonymized data. The 
study protocol was approved by the head of research governance at the lead 
clinical center.  
 
Data Extraction 
Anonymized data were remotely extracted from 19 centers using the same EMR 
system (Medisoft Ophthalmology, Medisoft Limited, Leeds, UK) in November 
2014.  Each site is the only NHS provider of diabetic retinopathy care to their 
local population and very few patients switch between providers or access care 
privately. All patients were first time presenters to eye providers after being 
referred from UK national diabetic retinopathy screening program, a nationwide 
program implemented through the National Health Service (NHS) and maintained 
by rigorous quality assurance measures.15 Patients who received anti-vascular 
endothelial growth factor (anti-VEGF) injections during the study period were 
excluded. Data was extracted through the EMR compulsory DR structured 
assessment module as described previously.16 Demographic data was extracted 
from the hospital’s patient administration system to the EMR. All patients had 
data extracted from the time of their first DR structured assessment entry onto 
the EMR to the date of their last clinical entry before the data extraction on 
November 26th, 2014.  
 
EMR recording of Clinical Variables 
Physicians were asked to fill out the characteristics of retinopathy and 
maculopathy findings on drop down menus. Each retina evaluation screen 
showed the standard ETDRS 8a4 and 2a4 photos for IRMA and DBH, 
respectively. The following non-proliferative features were included: IRMA 
(choices of none, <8a in 1-4 quadrants, >8a in 1 quadrant, >8a in 2 quadrants, 
>8a in 3 quadrants, >8a in 4 quadrants), venous beading (none, 1 quadrant, 2 or 
more quadrants), venous loops/reduplication (yes or no), hemorrhages (none, 
MA only, hemorrhages <next level, >=4 blot hemorrhages in any quadrant and 
>=8 in total, >=2a in any quadrant, >2a in all quadrant), cotton wool spots (none, 
<=5, >5). The fields that were required to define ETDRS grade were compulsory.  
 
Clinical Variables 
Clinical features that were extracted include presence and extent of the following 
features: microaneurysms (MA) only, hemorrhages/microaneurysms < standard 
ETDRS photograph 2a4, > 4 dot blot hemorrhages (DBHs) in any quadrants and 
> 8 in total, DBHs > standard ETDRS photograph 2a4 in any quadrant, DBHs > 
standard ETDRS photograph 2a4 in all quadrants, intraretinal microvascular 
abnormalities (IRMA) > standard ETDRS photograph 8a4 in 1 quadrant, venous 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 5 
beading, venous loops/replication, cotton wool spots, and scars of prior 
photocoagulation. The composite ETDRS scores were automatically generated 
in the EMR.  
 
Statistical Analyses 
Eyes with neovascularization at baseline were excluded from survival analyses. 
Kaplan-Meyer survival curves were generated to demonstrate the rate of 
progression to PDR based on each clinical feature. Cox proportional hazards 
regression models were used with baseline age, gender, presenting visual acuity 
as prognostic variables. The primary outcome was the time from the date of 
patients’ first eye examination until the first time of the respective grade of 
retinopathy. If the eyes did not reach the respective retinopathy, they were 
censored at the time of their latest follow up examination. Time to PDR or VH 
analyses were stratified by baseline diabetic retinopathy status. All analyses 
were performed at the patient eye level, and analyses were repeated with 
random selection of one eye per patient to evaluate the intercorrelation. All 
statistics were performed using R version 3.2.5 (http://www.r-project.org).  
 
RESULTS 
A total of 64,225 eyes (33,598 patients) were identified with a structured DR 
assessment.  13,971 eyes (1,045 patients) were excluded due to anti-VEGF 
injections. A total of 50,254 patient eyes (32,553 patients) were included in the 
study. The mean age was 64.89 (IQR 55.10 to 76.68), and 63.97% were 
Caucasian. The overall mean presenting visual acuity was 72.60 ETDRS letters 
(IQR 70.0 to 85.0) (Table 1). Diabetic retinopathy was present in 72.4% of 
diabetic patients at initial presentation to an eye care provider.  
Progression to Proliferative Diabetic Retinopathy by DR Severity 
The percentages of progression to PDR by year 1, 3, 5 per baseline DR were the 
following: No DR (0.3%, 1.0%, 2.2%, respectively), very mild (0.7%, 3.8%, 7.9%), 
mild (1.5%, 6.9%, 13.0%), moderate (4.0%, 16.1%, 27.2%), severe (9.6%, 
31.6%, 45.5%), and very severe NPDR (24.7%, 55.8%, 67.7%) (Figure 1). 
The hazard of progressing to PDR in patient eyes that presented with very mild 
and mild NPDR compared to no DR were 4.02 (95%CI 3.25 to 4.96) and 6.71 
(95%CI 5.46 to 8.24), respectively after adjusting for age, gender, race, and initial 
VA. Furthermore, in comparison to the patient eyes with no DR, the hazard of 
PDR progression in moderate, severe, and very severe NPDR were 14.8 (95%CI 
12.1 to 18.1), 28.2 (95%CI 22.9 to 34.7), 58.4 (95%CI 47.0 to 72.7), respectively 
after adjusting for age, gender, race, and initial VA (Table 2). 
Progression to Proliferative Diabetic Retinopathy by DR Features 
In subanalysis that included only patient eyes with severe NPDR (n=2823), a 
total of 715 eyes with IRMA, 240 eyes with venous beading and 169 with 4Q 
DBHs were found. In this group, the percentages of progression to PDR by year 
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1, 3, 5 were highest in patient eyes with IRMA (10.5%, 31.7%, 49.0%, 
respectively), followed by 4Q DBHs (5.9%, 34.7%, 40.8%) and venous beading 
(5.0%, 17.2%, 39.9%) (Figure 2).  
The presence of IRMA was associated with 1.77 fold higher chance of 
developing PDR than venous beading in two quadrants (95%CI 1.25 to 2.49) 
after adjusting for age, gender, race, and initial VA. Similar trend was seen with 
4Q DBHs but this was not statistically significant (HR 1.47, 95%CI 0.94 to 2.31) 
(Figure 2) (Table 2). 
Progression to Vitreous Hemorrhage by DR Severity 
The percentages of progression to VH by year 1, 3, 5 per baseline DR were the 
following: No DR (0.3%, 0.7%, 1.1%, respectively), very mild (0.2%, 0.8%, 1.8%), 
mild (0.3%, 1.3%, 2.9%), moderate (0.6%, 3.3%, 7.3%), severe (0.9%, 4.7%, 
9.8%), and very severe NPDR (3.0%, 10.9%, 17.8%) (Figure 3). 
In comparison to patient eyes with no DR, the eyes with very mild NPDR at 
baseline were 1.68 times more likely to progress to VH (95% 1.24 to 2.27) while 
mild, moderate, severe, and very severe NPDR were 2.56 (95%CI 1.91 to 3.42), 
5.60 (95%CI 4.26 to 7.36), 7.29 (95%CI 5.41 to 9.84), 12.6 times more likely to 
develop VH (95%CI 9.03 to 17.6), respectively after adjusting for age, gender, 
race, and initial VA (Table 2). 
Progression to Vitreous Hemorrhage by DR features 
In subanalysis that included only patient eyes with severe NPDR (n=2823), the 
rates of progression to VH by year 1, 3, 5 were highest in eyes with baseline 4Q 
DBHs (4.5%, 7.3%, 13.8%), followed by IRMA (0.3%, 2.2%, 9.7%) and venous 
beading (1.3%, 4.3%, NA) (Figure 4).  
When comparing the risks associated with specific clinical features, 3.84 fold of 
statistically significant increase in hazard of developing VH (95%CI 1.39 to 10.6) 
was associated with the presence of 4 quadrants of DBHs compared to venous 
beading. Near 50% increase with IRMA was seen compared to venous beading, 
but this was not statistically significant (HR 1.42, 95%CI 0.44 to 3.66) (Figure 4) 
(Table 2). 
Analyses with One Eye Selection 
To rule out any significant effect for bilateral eye correlation, only one eye was 
randomly selected per patient and analyses were repeated. The results did not 
change significantly: compared to no DR, the hazard of progressing to PDR from 
mild NPDR was 6.56 (95%CI 5.06 to 8.51), while from moderate and severe 
NPDR were 13.9 (95%CI 10.8 to 17.9) and 26.5 (95%CI 20.5 to 34.4), 
respectively. Compared to venous beading, the eyes with IRMA and 4Q DBH 
were 1.57 (95%CI 1.06 to 2.31) and 1.15 (95%CI 0.67 to 1.97) more likely to 
progress to PDR, respectively. Regarding the progression to VH, mild NPDR had 
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2.63 (95%CI 1.81 to 3.81) times higher hazard, while moderate and severe 
NPDR had 5.43 (95%CI 3,82 to 7.71) and 7.66 (95%CI 5.25 to 11.2) higher HR 
compared to no DR, respectively. The hazard of progressing to VH in the eyes 
with 4Q DBH and IRMA were 4.25 (95%CI 1.32 to 13.6) and 1.53 (95%CI 0.54 to 
4.36) higher than venous beading, respectively.  
 
DISCUSSION 
This paper demonstrates that more than 20 years after the original Airlie House 
classification and ETDRS studies, baseline severity of DR continues to predict 
patients’ clinical outcomes. Approximately 44-56% of patients with severe or very 
severe NPDR progressed to proliferative diabetic retinopathy or vitreous 
hemorrhage in less than three years. Among three main clinical features of 
severe NPDR (4Q DBHs, IRMA, and venous beading), the most significant 
feature predictive of PDR progression was IRMA, while the presence of 4Q 
DBHs was the most significant risk factor for VH.  
The prevalence of DR in our hospital eye clinic based study population was 
72.4% at initial examination, with very mild and mild NPDR being the most 
common. Severe DR was more common in younger men. The UK has a 
community-based whole population retinopathy-screening program for people 
with diabetes. 17 Patients with diabetes in the hospital eye services have 
therefore, been referred by their local screening program due to an increased risk 
of sight-threatening DR, DME, or for another ocular condition e.g. cataract or 
glaucoma. Thus, the finding of nearly 30% of no DR may be explained by 
patients with unilateral DR/DME or who have been referred due to other ocular 
conditions.  
Previous epidemiology studies have reported varying rates of progression to 
PDR. The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) 
reported 9% rate of progression to PDR over 4 years in patients who present with 
early retinopathy at baseline.6 A UK cohort of 20,686 patients without PDR or 
maculopathy at initial DR screening between 1990 and 2006 showed an 11% 
cumulative incidence of PDR at 10 years among 3632 patients with NPDR at 
baseline.7 The Beijing Eye Study of 170 subjects showed a 35% overall 
progression rate in subjects with baseline DR and 21% in patients with no 
baseline retinopathy during 2001 to 2006 period.18 Other studies have shown 
rates of progression to PDR ranging from 5.3% to 8.2% at 4 to 9 years of follow-
up in patients with baseline mild or unspecified severities of NPDR.8-10 
In contrast to epidemiologic studies, data from clinical trials originate from much 
smaller sample sizes and similarly variable results. ETDRS, one of the largest 
clinical trials, included a total of 3711 patients between 1980 and 1985, showed 
65.3-82.8% progression rate from severe NPDR to PDR in 5 years;4 however, its 
study period predates most current standards of care for retinopathy.19 More 
recently, RISE and RIDE trials recruited 377 and 382 patients, respectively, to 
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compare the treatment outcomes of patients with diabetic macular edema.20 Less 
than 150 patients that were treated with sham injection provide the progression 
data and 8.7-10.5% rate of progression of >2 steps in 2 years were reported. 
Similarly, a 12.3% incidence of 2-step progression was found in the placebo arm 
(1012 patients) of the Fenofibrate Intervention and Event Lowering in Diabetes 
(FIELD) study during 5 year follow up.21 In the Action to Control Cardiovascular 
Risk in Diabetes (ACCORD) study which included 2856 patients, the control 
group had a 10.4% of >=3 step progression during 4 year follow up.22 A 20% rate 
of 2-step progression was found in 595 patients with baseline retinopathy during 
5 years in the Veterans Affairs Diabetes Trial (VADT).23 
Our progression rates were lower than in ETDRS but slightly higher than the 
rates reported in more recent population studies and RCTs.7-10A meta-analysis 
that included 27,120 diabetic patients from 28 studies showed pooled incidence 
of PDR 11.0% in 4 years.24 Interestingly, when stratified for time period, the 
incidence of PDR was 19.5% in 1975-1985 while 2.6% in 1986-2008 in 4 years, 
indicating improved diabetic care in recent years. Thus, our cohort’s lower 
progression rate than ETDRS is not surprising. In addition, our study population’s 
higher progression rate than more recent studies could likely be explained by a 
selection bias. All our patients were referred from community DR screening 
centers and we would expect our study population to be enriched for patients 
with more severe baseline retinopathy and therefore at a greater risk of 
progression. In addition, the rate differences between our study and others may 
include varying diabetic control status of the study population, the cohort bias 
due to varying study generations, and changing patterns in diabetic care that 
could have led to different incidence of PDR.  
The simplified features of severe NPDR were largely defined from landmark trials 
such as DRS and ETDRS. Our study demonstrates that the presence of 4Q 
DBHs and IRMA are significantly more predictive of progression than venous 
beading. Interestingly, while IRMA was the most important risk factor predictive 
of PDR progression, the risk of VH was higher in patients with 4Q DBHs 
compared to those with IRMA or venous beading. IRMA has been shown to be a 
precursor of neovascularization elsewhere (NVE) in a longitudinal case 
evaluation with spectral-domain optical coherence tomography (OCT),25 thus 
likely explains why IRMA was the most predictive of PDR. A possible explanation 
for the disconcordance in the risk factor for PDR vs. VH is that IRMA may lead to 
NVEs that are less likely to hemorrhage than 4Q DBHs. Given that venous 
beading does not appear as critical as the other two features in predicting PDR 
or VH, and since IRMA vs. NVE can be distinguished with OCT,25 the evaluation 
of venous beading with or without FA may become a less important in future if 
validated in other cohorts. It may also indicate that ophthalmologists in real world 
settings record IRMA and VH more routinely or reliably than venous caliber 
change. 
Our study suggests that current-screening guidelines of at least an annual 
screening examination for all patients with diabetes may not detect new cases of 
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PDR as often as previously thought, although screening also serves the purpose 
of detecting DME.26 Only 2.3-8.6% of patient eyes that had no DR or very mild 
NPDR and had not required anti-VEGF treatment progressed to PDR in 5 years. 
Similarly, the 4-year incidence of PDR in patients with no baseline DR was 2.8% 
(33/1164) in a meta-analysis that included 14 studies conducted during 1986 and 
2008.24 Nevertheless, 0.3-0.8% of these eyes progressed to PDR in 1 year, 
suggesting that more specific, feature-based criteria would be advantageous in 
determining the appropriate frequency of follow-up. Our study findings need to be 
replicated and validated in future studies prior to recommending different 
intervals; however, this highlights the importance of understanding varying risks 
of individual clinical feature when evaluating patients with severe DR, which may 
result in different follow up frequency for each individual patient or different 
systemic or ocular treatment algorithms.  
Our study results may not be generalizable to other populations of different 
income settings beyond the UK. Other countries may differ in baseline rate of 
diabetes or quality of diabetes control. Nevertheless, the results reveals that 
IRMAs and hemorrhages are still key clinical signs (which can be diagnosed on 
clinical examination or photography) with respect to progression to PDR/VH, 
therefore these features should be highlighted when training staff (technicians, 
nurses, physicians) involved in DR screening in any setting or countries. Future 
studies on the effect clinical features in DR progression in different settings will 
provide further insights.  
 
The main strengths of our paper include large sample size with granularity of the 
clinical data above what is available in a conventional free test EMR.  However, 
the main limitation is that our data is dependent on the quality of each 
examination and recording in EMR. Our study EMR demonstrated ETDRS 
standard photos next to the clinical exam section to improve each physician’s 
examination, and all participating retina physicians were instructed to complete 
all sections of structured data entry as mandated fields when diabetic retinopathy 
grading was performed. However, our exam results do not originate from 
stereoscopic photo evaluations in a reading center such as in RCTs, thus may 
differ from other clinical trials. Nevertheless, large epidemiologic or clinical 
studies are becoming increasingly more difficult and costly to perform, and the 
results of real world practice provide equally important, but different information. 
Future studies to assess the quality and reliability of fundus grading in the study 
EMR will be valuable. 
Additional limitations include unknown status of confounders such as type of 
diabetes, level of hyperglycemia and hypertension in our patients.27 The type of 
diabetes mellitus (I or II) may influence the risk of PDR and VH differently, but 
this information was not recorded in our EMR. In addition, our study did not 
include patients who received anti-VEGF, which likely affects the rate of DR 
progression.28 Further stratified analyses of DR progression in patient eyes with 
or without DME are planned in our subsequent report. 
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Proliferative diabetic retinopathy and vitreous hemorrhage are important 
endpoints of sight-threatening diabetic retinopathy. Our study demonstrates that 
baseline diabetic retinopathy severities and clinical features of initial diabetic 
retinopathy screening remain key prognostic factors. The EMR facilitated feature-
based evaluations of diabetic retinopathy provides not only a large cohort of 
patients for epidemiological study but also the basis for large clinical studies in 
which important outcome predictors can be assessed. 
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FIGURE CAPTIONS 
 
Figure 1. Kaplan-Meyer curves on survival analyses in progression to 
proliferative diabetic retinopathy (PDR), stratified by severity of diabetic 
retinopathy (DR) at initial evaluation. Time to PDR is associated with baseline 
DR severity after adjusting for age, gender, race, and starting visual acuity. x-
axis, time in year. y-axis; percentage of patient eyes at risk; NPDR, non-
proliferative diabetic retinopathy. Shaded areas represent 95% confidence 
intervals. 
 
Figure 2.Kaplan-Meyer curves on survival analyses in progression to proliferative 
diabetic retinopathy (PDR), stratified by presence of different clinical features 
at initial evaluation. Compared to the eyes with venous beading, the eyes 
with intraretinal microvascular abnormalities (IRMA) had a 
significantly increased risk of developing PDR. x-axis, time in year. y-axis; 
percentage of patient eyes at risk; IRMA, intraretinal microvascular 
abnormalities; DBH, dot blot hemorrhages. Shaded areas represent 95% 
confidence intervals. 
 
Figure 3.Kaplan-Meyer curves on survival analyses in progression to vitreous 
hemorrhage (VH), stratified by severity of diabetic retinopathy (DR) at initial 
evaluation. Time to VH is associated with baseline DR stage after adjusting 
for age, gender, race, and starting visual acuity. x-axis, time in year. y-axis; 
percentage of patient eyes at risk; NPDR, non-proliferative diabetic 
retinopathy. Shaded areas represent 95% confidence intervals. 
 
Figure 4.Kaplan-Meyer curves on survival analyses in progression to vitreous 
hemorrhage (VH), stratified by presence of different clinical features at initial 
evaluation. Compared to the eyes with venous beading, the eyes with 4 
quadrant dot blot hemorrhages had a significantly increased risk of 
developing VH. x-axis, time in year. y-axis; percentage of patient eyes at risk; 
IRMA, intraretinal microvascular abnormalities; DBH, dot blot hemorrhages. 
Shaded areas represent 95% confidence intervals. 
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Table 1. Demographic and Baseline Clinical Characteristics of Patient Eyes. 
 
 No DR  Very Mild    
    NPDR 
       Mild NPDR    Moderate    
     NPDR 
   Severe NPDR         Very Severe    
            NPDR 
Total 
n 16762 16081 12856 10909 2823 823 50254 
Age (SD) 71.75 13.74 63.46 15.24 63.00 14.72 60.99 14.95 50.00 14.90 57.98 14.77 64.89 15.31 
Male (%) 8126 48.47 9001 56.03 7487 58.24 6468 59.29 1779 63.04 496 60.27 33366 55.38 
Caucasian (%) 11487 68.52 9941 61.82 7795 60.63 6986 64.04 1764 62.51 569 69.14 38542 63.97 
Right eye (%) 8373 49.95 7938 49.36 6480 50.40 5480 50.23 1419 50.28 402 48.85 30092 49.94 
Mean VA (SD) 67.14 25.68 74.97 17.79 74.42 17.19 84.89 16.62 74.17 18.06 71.09 20.36 72.60 20.30 
DR, diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; SD, standard deviation; VA, visual acuity (Early Treatment 
Diabetic Retinopathy Study). 
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Table 2. Multivariate Cox Regression Analyses on Progression to Proliferative Diabetic Retinopathy or Vitreous Hemorrhage.  
 
Progression to PDR Progression to VH 
 HR 95% CI p value HR 95% CI p value 
Age 0.98 0.97   0.98  < 2x10-16 0.98 0.97   0.98  < 2x10-16 
Gender 0.95 0.89   1.01 0.093 1.08 0.96   1.23 0.20 
Non-caucasian 0.94 0.89   1.00 0.65 0.76 0.66   0.87 6.80 x10-5 
VA 0.99 0.98   0.99  < 2x10-16 0.98 0.98   0.98 < 2x10-16 
DR level 
      
  no DR Ref   Ref   
  very mild NPDR 4.02 3.25   4.96  < 2x10-16 1.68 1.24   2.27   8.1 x10-4 
  mild NPDR 6.71 5.46   8.24  < 2x10-16 2.56 1.91    3.42 2.36x10-10 
  moderate NPDR 14.80 12.10   18.09  < 2x10-16 5.60 4.26    7.36  < 2x10-16 
  severe NPDR 28.19 22.92   34.67  < 2x10-16 7.29 5.41   9.84  < 2x10-16 
  very severe NPDR 58.42 46.95   72.70  < 2x10-16 12.60 9.03  17.57  < 2x10-16 
 Progression to PDR Progression to VH 
 HR 95% CI p value HR 95% CI p value 
Age 0.99 0.98   0.99 0.0056 0.97 0.95  0.99 0.039 
Gender 0.92 0.71   1.19 0.53 1.20 0.60  2.40 0.61 
Non-caucasian 1.01 0.77   1.31 0.96 0.76 0.27  1.59 0.47 
VA 0.99 0.98   0.99 1.60x10-5 0.97 0.96  0.98 2.55x10-13 
DR Feature 
      
  Venous beading Ref   Ref   
  4 quadrants DBH 1.47 0.94   2.31 0.88 3.84 1.39  10.62 0.0095 
  IRMA 1.77 1.25   2.49 0.0013 1.42 0.55   3.66 0.47 
PDR, proliferative diabetic retinopathy; VH, vitreous hemorrhage; HR, hazard ratio; CI, confidence interval; VA, visual acuity; DR, 
diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; DBH, >2A dot-blot hemorrhages; IRMA, inner retinal microvascular 
abnormalities.  
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